Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

3 Customer Reviews

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M2nBe2Z2dmO2aX;uJGF{e2G7 M1XzdVIh|ryP NFLYfmIyKGh? MoDObY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg NYC4O3BvOjZ|NkOxPVE>
C2C12 NX;F[ZhvTnWwY4Tpc44hSXO|YYm= M1rHeFHDqM7:Zz;tcC=> NVmxNHR1OcLiaB?= Mn\1ZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> M1;MeVI3OjlzMke5
MEFs WT M1;obWZ2dmO2aX;uJGF{e2G7 MoXHOeKh|ryP M1rWXlIxKG2rbh?= MnvGZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? MlrxNlYyQTZyMkO=
MEFs VAMP7 KO NEnjXW1HfW6ldHnvckBCe3OjeR?= MlvIOeKh|ryP NGO4cW8zOCCvaX6= NFP1c3dk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU NXv3ZmRtOjZzOU[wNlM>
SMCs MYrGeY5kfGmxbjDBd5NigQ>? MY[xNOKhyrWpL33s MWCwMVEzKGh? M{PVPGROW09? NYXLUGlVe2ixd4OgZUB1emWwZDD0c5diemS|IHGgbIlocGW{IHPvcoNmdnS{YYTpc44hd2ZidHjlJGVTN1OUIH7leJdwemtiaX6geIhmKHCncnnueYNt\WG{IHHy[YHDqA>? M4PzUFI3OTd{MEiw
SMCs Ml\rSpVv[3Srb36gRZN{[Xl? NEj3NWIyOMLiwsXnM41t M3exblAuOTJiaB?= MUDEUXNQ M2D3VoNifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? NYXmSJRqOjZzN{KwPFA>
HEMC-1 M1TDZWZ2dmO2aX;uJGF{e2G7 M3XtSFAvOcLiwsXnM41t NXfaUXdUOjUEoHi= MWPjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= MlG2NlU6PzJ5NUm=
HUVEC NUn0SFZkTnWwY4Tpc44hSXO|YYm= M32y[FExyqEQvF2= M{HlOVHDqGh? NHzr[WhFVVOR M3S3NoFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W| M4jxO|I2QTV4OUi4
HUVEC NVHucYxpTnWwY4Tpc44hSXO|YYm= NFPsd3MyOMLizszN MmnwNeKhcA>? M{LON2ROW09? MVnpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn NX7jcXI2OjV7NU[5PFg>
Caco-2 M2q1[2Z2dmO2aX;uJGF{e2G7 NYjxb|d[Oi53IN88US=> NV7FTVZUOzBibXnu MYnheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> MV6yOVk2PDl|MR?=
NRK NIHIPXBHfW6ldHnvckBCe3OjeR?= Mm\CNlAx6oDHbnevcYw> M1y3eVTjiIWq MXvEUXNQ MXjy[ZNkfWW|IH3peI91cWNicILv[5Jme3Orb36= NF36R2IzPTl2OEW4Oi=>
HeLa NYnic4l[TnWwY4Tpc44hSXO|YYm= NFXxXYkzODEkgJXu[{9udA>? MYqzJIg> MojRSG1UVw>? MWrpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 Mk[2NlU6PDh3OE[=
COS M3WzPWZ2dmO2aX;uJGF{e2G7 NFnweoMyKM7:Zz;tcC=> MVqzJIg> MmG0Z49ueGyndHXsfUBlcXOyZYLz[ZMhfGinIFHQMVEhe2mpbnHsxsA> MWiyOVkyPTlyMB?=
DF1  NXyw[XlYTnWwY4Tpc44hSXO|YYm= MXyxxsDPxE4EoB?= NEHKfFc1QCCq NITaOFdFVVOR MnPG[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= NHPGWZkzPThyN{C1OC=>
nHDFs  M36zdWZ2dmO2aX;uJGF{e2G7 NFfJVWMyyqEQvF5CpC=> M3nKfVLDqGh? NEO1N4hxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= M13tc|I2Pzd{NkG2
FRT  MlXmSpVv[3Srb36gRZN{[Xl? MmPMOUDPxGdxbXy= MXGyxsBp MV7icI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= NEDCWGozPTd4N{GxOS=>
FRT  NXvDTnBOTnWwY4Tpc44hSXO|YYm= NYfPPI5MPSEQvHevcYw> M2HTeVLDqGh? Mnn2dJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm NGLPOJAzPTd4N{GxOS=>
HepG2  MoXrSpVv[3Srb36gRZN{[Xl? MoC1NgKBkcL3TdMg NUXvWXlTOjRiaB?= NHjy[FFFVVOR NETnOlhl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIGDYVkBuWk6D M4n4SlI2PjF4NUm3
SMCs NFiyc3hHfW6ldHnvckBCe3OjeR?= NIq2PGcy|rypL33M NVP4UGlSOyCq NHjuT4di[2O3bYXsZZRmeyCFTmDZNkBxem:2ZXnuJIlvKHSqZTDFVkBkd22yYYL0cYVvfCCjbnSgco8hdG:wZ3XyJINwNWyxY3HsbZpm\CC5aYToJJRp\SCJb3znbUBu[XKtZYNCpC=> MV2yOVU5QTR{NR?=
OB-6 NUXSfVVxSXCxcITvd4l{KEG|c3H5 NX\SXWVlOi55wrFOwG0> MojkOFghcA>? M1TL[4lv\HWlZYOgZZBweHSxc3nz NVzO[YF3OjV3M{K0PFA>
iPSC-CMs  MYjGeY5kfGmxbjDBd5NigQ>? NHPWWo42ODBibnevcYw> MkHLOFghcA>? M2faRYlv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? M{LQPFI2PDh6Nk[2
SP-Nluc MYPGeY5kfGmxbjDBd5NigQ>? MoD3OUBu\y:vTB?= MlTPOkBp NYr4W4pPTE2VT9Mg MoC2Z4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> MXOyOVM6Ojl7OB?=
PEXEL-Nluc NUHzN5VrTnWwY4Tpc44hSXO|YYm= NV3QNY03PSCvZz;tUC=> NFqxclY3KGh? MYjEUXNQyqB? MWfjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl NWDab49JOjV|OUK5PVg>
H1299 MWLGeY5kfGmxbjDBd5NigQ>? NGL3fpoyOCEQvHevcYw> MmTRNlQhcA>? M2rMU4lv\HWlZYOgZZV1d3CqYXf5xsA> MWqyOVM5QDl5MB?=
MDA-MB-231 NHnzOpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGHiWW8x6oDVNUCg{txoN22O NFvUXHQ1QCCq MXfFR|UxyqB;IECuNFE3KML3Zz;tUC=> NE\LWIczPTN3NkW2Oy=>
MDA-MB-231 NWmxfJNuSXCxcITvd4l{KEG|c3H5 MYewMlEh|rypL33M Mn7VOEBp Mn;VbY5lfWOnczDhdI9xfG:|aYO= MnvrNlU{PTZ3Nke=
MDA-MB-231 NISxSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\EToRUOC5yMT:wMlA2KM7:Zz;tUC=> MmXmNlQhcA>? Mnz3bY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDzeYIuTzFiY3XscEBl\WK{aYO= M1mydVI2OzV4NU[3
MDA-MB-231 MWDBdI9xfG:|aYOgRZN{[Xl? M1ewUVAvODYkgKOxJO69\y:vTB?= MXKyOEBp MkLrbY5lfWOnczDQRXJRKCiyb3z5JGFFWC2{aXLvd4UheG:ueX3ldoF{\S1zKTDjcIVifmGpZR?= NX[1[3l7OjV|NU[1Olc>
MDA-MB-231 NXmwfm5FTnWwY4Tpc44hSXO|YYm= MVew5qCUPTBizsznM41N NYrjWJc{OjRiaB?= MmfIbY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO= M2HZcVI2OzV4NU[3
A172 MYPGeY5kfGmxbjDBd5NigQ>? NXnET5ZVOTEEoN88[{9udA>? NG\Qd4M1yqCq MUfEUXNQyqB? NWr2cG0{emW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= MYmyOVI{QTVyNx?=
KMS-6 M{[xVmZ2dmO2aX;uJGF{e2G7 NYTZOnlrOcLizszNxsA> NWDrU2pmOjRiaB?= NVfTXm9W\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s NHzL[5IzPTJ{OUGyOi=>
MEC M{C3W2Z2dmO2aX;uJGF{e2G7 NFnpfFkyKM7:TR?= MVGxMlUhcA>? NXjsc5db[2G3c3XzJIEh\HKjbXH0bYMh\GWlcnXhd4UhcW5idHjlJJN2em[jY3WgWmVITlJ{ MkLMNlUzOjh6MUW=
HEK293/hERG NWO5V|MxTnWwY4Tpc44hSXO|YYm= MoLiNVDDqM7:TR?= M{jENFHDqGh? NWXWNIZ{emW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= NG\nSYkzPTJzOES2PS=>
RBE4 NV\pTW9CSXCxcITvd4l{KEG|c3H5 NFvlWVYzyqEQvF2= MVqz5qCUOjUEoHi= MnjhbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCmZYDlcoRmdnSueR?= MlmxNlUyOjhyMkW=
RBE4 MkLySpVv[3Srb36gRZN{[Xl? M1PvUVLDqM7:TR?= Mki3N-KBmzJ2wrDo M4LvdIlv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=> MV6yOVEzQDB{NR?=
RBE4 MlvNSpVv[3Srb36gRZN{[Xl? MWCyxsDPxE1? MoPKN-KBmzJ2wrDo NWjDfY1McW6lcnXhd4V{KGGldHn2[UBk[XOyYYPlMVEzKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? M4rqRVI2OTJ6MEK1
RBE4 NHHueo5HfW6ldHnvckBCe3OjeR?= MlLZNuKh|ryP NVXNVJVVO+LCk{K0xsBp MUHpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUT2OgeIlu\S2mZYDlcoRmdnSueR?= NELib5IzPTF{OECyOS=>
RBE4 M2fBb2Z2dmO2aX;uJGF{e2G7 MWKyxsDPxE1? NHzXSpY{6oDVMkVCpIg> MmnhbY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 MXqyOVEzQDB{NR?=
RBE4 MX3GeY5kfGmxbjDBd5NigQ>? MUOyxsDPxE1? M3HwPFPjiJN{NNMgbC=> MXrpcoR2[2W|IHHuJI93\XKub3HkJI9nKEOjMjxCpIlvKHSqZTDtbZRw[2ixbnTybYEhcW5idHjlJIZqenO2IEdCpIghd2ZiaX7jeYJifGmxbjCodQKBkT{kgJmwMlAxOSliYoX0JGNiOiwEoHzleoVteyCrbjD0bIl{KG:{Z3Hu[Yxt\SCmZXPy[YF{\WRiYX\0[ZIhOTMEoHigc4YhcW6ldXLheIlwdg>? M3jGN|I2OTJ6MEK1
Huh-7  Ml2wSpVv[3Srb36gRZN{[Xl? M4nSdFHPxGdxbVy= MVez5qCUOjUEoHi= MWPpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NGjPXoQzPTB{NkG3OC=>
HepG2  MWnGeY5kfGmxbjDBd5NigQ>? M{XncFHPxGdxbVy= M2T0ZVPjiJN{NNMgbC=> NFH6bnRqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MVmyOVAzPjF5NB?=
H838-LKB1 NF;FeG5HfW6ldHnvckBCe3OjeR?= NHOyVlY{OMLibnevcYw> MkCwNVIwOThiaB?= Mln2bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NGPJU2EzPTBzMUC4Ni=>
H838-KDLKB1  NXXjUowyTnWwY4Tpc44hSXO|YYm= MWCzNOKhdmdxbXy= NH71PIcyOi9zODDo MlT0bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NUHYOZZROjVyMUGwPFI>
H838-KDLKB1  MV\GeY5kfGmxbjDBd5NigQ>? MX:zNOKhdmdxbXy= MV6xNk8yQCCq NIrQNYVqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwbI9{eGixconsZZRm\CCnSV[y{tEhMHCqb4PwbI8u\UmIMt8xLS=> NVHJSGxROjVyMUGwPFI>
3T3-L1 M1;vOWZ2dmO2aX;uJGF{e2G7 M3HCWlUh|rypL33s MkHMN|AhdWmw MU\tbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? Mlz4NlQ5PDN6Mke=
3T3-L1 M1zBR2Z2dmO2aX;uJGF{e2G7 M{XQb|Uh|rypL33s MUizNEBucW5? M1\EcZJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? NH7ifm8zPDh2M{iyOy=>
3T3-L1 NUP5W|FwTnWwY4Tpc44hSXO|YYm= NXm0dHp4PSEQvHevcYw> M2i5cFMxKG2rbh?= MlPqZ4F2e2W|IILleoVze2mkbHWgdoVlcXO2cnnieZRqd25ib3[gS2xWXDR? NUTWfnZqOjR6NEO4Nlc>
3T3-L1 MmnMSpVv[3Srb36gRZN{[Xl? M2S2PFUh|rypL33s MV6xxsBp MkDtZ4F2e2W|IILl[Il{fHKrYoX0bY9vKG:oIFfMWXQ1KGK3dDDuc5QhcW6lcnXhd4UhcW5iZ3z1Z49{\SC3cIThb4U> MYmyOFg1Ozh{Nx?=
3T3-L1 Mlv3SpVv[3Srb36gRZN{[Xl? NF7jdmg2KM7:Zz;tcC=> NFzsZ|YyyqCq NEnLcVlk[XW|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5Rweg>? NFjSW4kzPDh2M{iyOy=>
HeLa  MoHGSpVv[3Srb36gRZN{[Xl? M3TQXVUh|rypL33s M122TFMhcA>? MmDtZ4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ MW[yOFg1Ozh{Nx?=
HEK293 Mn[1SpVv[3Srb36gRZN{[Xl? MUO1xsDPxGdxbXy= MYqxNuKhcA>? NILTe5Vi[m:uaYPo[ZMhS02DLXnu[JVk\WRiQ2LFUGQzKHOnY4LleIlwdg>? NHvSfWszPDZ6N{SzNS=>
COS-1 NETubmJHfW6ldHnvckBCe3OjeR?= M4jWR|UhyrWpL33s Mo\oNlQhcMLi M3TmdZJme3S{aXP0d{Btd2OjbHn6ZZRqd25ib3[gUmIhcW5idHjlJJBmemmwdXPs[YFzKHKnZ3nvcuKh NWW1SWwyOjR4N{G3OVE>
PRP MXnGeY5kfGmxbjDBd5NigQ>? NH3YTGYyOCEQvF2= MVfhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? M163b|I1PjZ6N{Ww
RAW264.7 M2mwfGFxd3C2b4Ppd{BCe3OjeR?= M1\4VVQh|ryP NG\tZYg1QCCq MoLoZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? NXrmNYdPOjR4M{mwN|I>
MDMs M1nOOmFxd3C2b4Ppd{BCe3OjeR?= MXGxNQKBkc7:Zz;tcC=> NFPyNm4yOi9zNTDo MoP2bY5lfWOnczDhdI9xfG:|aYO= M1zxTFI1PTV4Nkm1
PMHs  NE\YflVHfW6ldHnvckBCe3OjeR?= MWSxNQKBmzJy4pEJ{txoN22u NWPWfVRqOjUkgJno M3HSSGROW09? MlHabY5lfWOnZDDFVkB{fHKnc4O= MW[yOFQxPzJ2Mh?=
PMHs  NHHjV3ZCeG:ydH;zbZMhSXO|YYm= MVqxNQKBmzJy4pEJ{txoN22u NEXFd2wzPOLCiXi= M1jJZWROW09? NWSwdo5zcW6lcnXhd4V{KGOnbHyg[IVifGh? MUeyOFQxPzJ2Mh?=
HEK293/tau NVfsXGhITnWwY4Tpc44hSXO|YYm= MXW1JO69VQ>? NFrvXFQyNzJxNDDo M1rRVYlv\HWlZYOgS49t\2liZoLh[41mdnSjdHnvcuKh NEPoOIUzPDN4OEC4PS=>
HEK293/tau MYDGeY5kfGmxbjDBd5NigQ>? MlrmOUDPxE1? MUmzJIg> M4rFSYlv\HWlZYOgeIF2KGi7cHXydIhwe3Cqb4L5cIF1cW:w MnjpNlQ{PjhyOEm=
ADF MmTVSpVv[3Srb36gRZN{[Xl? M4D2fFExKM7:TR?= NYfZSGJ1OTZiaB?= M4q2U4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV NHPQXWQzPDJ{OEKzNi=>
U373  Mnn0SpVv[3Srb36gRZN{[Xl? MX2xNEDPxE1? NXjEcWNEOTZiaB?= MlPGbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NVH2XYl{OjR{MkiyN|I>
RKO-HIPK2i M2DvWWZ2dmO2aX;uJGF{e2G7 NYPmRlRyOTBizszN NYHxUmRUOTZiaB?= NUfORYtVcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? MX6yOFIzQDJ|Mh?=
ADF  MoG3SpVv[3Srb36gRZN{[Xl? MkXNNVAh|ryPwrC= NH7FeoQ3KGh? MYnpcZBicXK|IITo[UBFSyCjY4TpeoF1cW:w NXPBSYg1OjR{MkiyN|I>
Huh7 NGHqT4lHfW6ldHnvckBCe3OjeR?= M1n5dVUh|rypL33s NXLVO5FUPCCq MVvhZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C NHPaO5kzPDFyMEG0NC=>
Huh7 M3\PcGZ2dmO2aX;uJGF{e2G7 Ml7XOUDPxGdxbXy= NH7ndIIyKGh? M2TUWYNifXOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIFHwc2Iu[3Knc3PlcpR{ NFTD[WwzPDFyMEG0NC=>
Huh7 MXTGeY5kfGmxbjDBd5NigQ>? MkDPOgKBmzFywrDu[{9udA>? MnvpNVIhcA>? MX3pcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= NEPKNWozPDFyMEG0NC=>
BAECs NYj1R2ZQTnWwY4Tpc44hSXO|YYm= M{C1bFUh|rypL33s NUTqbII{OC12IHi= MkXHbY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 NWG4fG9uOjRyOEWyNlU>
Macrophages MVLGeY5kfGmxbjDBd5NigQ>? MVO3NUDDvU1? NV\PRmIyPiCq MmK4bY5pcWKrdIOgcJVv[XOrbjDpcpRmem6jbHn6ZZRqd28EoB?= M3XLcFI1ODN7N{Sw
Colo 205 M1HkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLCNE02KM7:Zz;tUC=> MYi0PEBp MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O MmXtNlM6PzN7OU[=
Colo 205 Ml;VSpVv[3Srb36gRZN{[Xl? M33wNVAvODF{LUCuNFI2KM7:Zz;tUC=> M4DHUVE1KGR? MYjy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? M4SxPFI{QTd|OUm2
Colo 205 Mk\iRZBweHSxc3nzJGF{e2G7 MWmwMlEh|rypL33M NVv4R5ljOC1{NDDo NYG5[YNlcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= M2\WUFI{QTd|OUm2
Colo 205 M4jMZ2Z2dmO2aX;uJGF{e2G7 MoXCNE4xOTVizsznM41N Mm[5NlQhcA>? M2G2SYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? NFPke2ozOzl5M{m5Oi=>
Colo 205 MV\GeY5kfGmxbjDBd5NigQ>? M1zXc|AvODF3IN88[{9uVA>? MnrYNlQhcA>? MUPpcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiTV3Qdy=> M3noT|I{QTd|OUm2
IBRS2 MXnGeY5kfGmxbjDBd5NigQ>? M4jUdFUh|rypL33s MmHkNE42KGh? M{XLRWROW09? NEDwN2VlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? M4LMZVI{QTZ|NUO0
IBRS2 MUDGeY5kfGmxbjDBd5NigQ>? M2\nVlUh|rypL33s MWmwMlUhcA>? M2L5TWROW09? NXvBdmls\W6qYX7j[ZMhTk2GVjDpcoZm[3Srb36= MVKyN|k3OzV|NB?=
HeLa M1vHU2Z2dmO2aX;uJGF{e2G7 M2HmcFIh|ryP NEXVdZUzKGkEoB?= NYG5UXlG[XS2ZX71ZZRmeyC2aHWgWG5HNWmwZIXj[YQhe2WlcnX0bY9vKG:oIFnMMVE2 NIDxTlAzOzl3MEi5Ni=>
HFS  NInyS3RHfW6ldHnvckBCe3OjeR?= M3T5NlAuOSEQvHevcYw> NWXGSY5UOjRiaB?= NITy[HhIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t NHPQNpgzOzh7NE[zNy=>
HFS  NUntPHFrTnWwY4Tpc44hSXO|YYm= NW\LNW03OC5yMTFCuYcwdWx? M2jte|I1KGh? NGDKOJBqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq MYKyN|g6PDZ|Mx?=
OVCAR-3 M1HjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoryNgKBmzF3wrFOwG3DqA>? NGDDd3ozPMLiaB?= NFfSN2ZqdmS3Y3XzJIEhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7wrC= MnS3NlM5OjZ7NkS=
OVCAR-3 NW\DS4ZTTnWwY4Tpc44hSXO|YYm= NFi1bZoy6oDVMUZCpO69VcLi M{HLZ|I1yqCq MXzpcoR2[2W|IH71Z4xm[XJiZHHtZYdm M1KyR|I{QDJ4OU[0
OVCAR-3 MXPBdI9xfG:|aYOgRZN{[Xl? NG\aUWsyNTFywrFOwG0> Mnj4OEBp MmL0bY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= MkHNNlM5OjZ7NkS=
OVCAR-3 MUnBdI9xfG:|aYOgRZN{[Xl? NWGzW4lkOTEEoN88US=> M4TrclI1yqCq MnzRbY5lfWOnczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4V{ NILTUI4zOzh{Nkm2OC=>
OVCAR-3 MYLGeY5kfGmxbjDBd5NigQ>? NXPCemFHOeLCk{GwxsDPxE1? MoXHNlTDqGh? MlLDbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs MYmyN|gzPjl4NB?=
OVCAR-3 NVH2flE2TnWwY4Tpc44hSXO|YYm= MXOx5qCUOTEEoN88US=> MY[yOOKhcA>? MmrLbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= NV\TUIp[OjN6Mk[5OlQ>
OVCAR-3 M1v4bmZ2dmO2aX;uJGF{e2G7 M{nmdVHjiJNzMNMg{txO NWTVdW5QOjUEoHi= NWLnTnhJcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NFTuU2IzOzh{Nkm2OC=>
MKN45 NFLPNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv0SJNKSzVyPECuNFAyKM7:Zz;tcC=> MmnhNlM4QTN|NEK=
LOVO MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXjWlNKSzVyPUCuNVIh|rypL33s NEjsdIczOzd7M{O0Ni=>
A549 M4HRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHrTWM2OD1yLkC0JO69\y:vbB?= MlvjNlM4QTN|NEK=
MDA-MB-435 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Jbmo2UUN3MEywMlAxOSEQvHevcYw> M3;2W|I{Pzl|M{Sy
HepG2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFraN3RKSzVyPECuNFAyKM7:Zz;tcC=> NVXGboUyOjN5OUOzOFI>
HL-60 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRDBwMECxJO69\y:vbB?= NGfSZ5IzOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID